Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses major regulatory and policy differences between the European Union and the United States.
Transcript:
What are some of the major regulatory and policy differences between biosimilars in the US and the EU?
In the European Union, they’ve had biosimilars than the US—they’ve had them in clinical practice for about 11 years. Comparing the two systems is very challenging in a lot of ways, but there are some fundamental differences. A couple of the main differences are that the European Union doesn’t require an additional level or designation of interchangeability to drive automatic substitution. In the US, the FDA requires that, so there will be no automatic substitution unless the interchangeability designation is met. So that’s a pretty significant difference because of the investment required to obtain that designation. There are also changes in naming and labeling. In terms of naming, the European Union determined that there does not need to be a suffix, so no designation because the biosimilars, as they will in the US, have a separate brand name but the generic name or the INN looks the same. Lastly, with labeling, labels in general look very different in the US versus the EU but there’s very little distinction in terms of biosimilar label versus the reference product, in part because the EU has more experience potentially, so there are some key differences. I think the biggest though is interchangeability and I think time will tell as to what that designation means in terms of value to all stakeholders, health plans, physicians, and patients.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
GRx+Biosims: Panelists Discuss Regulatory Shifts in Biosimilar Interchangeability
October 22nd 2024At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations in the US, discussing the FDA's new draft guidance, the removal of switching study requirements, and the need for more education to reduce misinformation and improve biosimilar uptake.